We are delighted to announce that Accord Healthcare was the most recognised company at the Global Generics & Biosimilar Awards 2018, having won awards for: Company of the Year and Biosimilar Initiative of the Year. As well, Intas & Accord Healthcare also picked up the award for Company of the Year Asia-Pacific.
Pelgraz - a pegylated G-CSF Biosimilar, is latest addition to Accord Healthcare's established por
Accord Healthcare is pleased to announce EC approval has been granted for its purchase of European Economic Area (EEA) rights to a basket of 13 products from TEVA.
Following a major acquisition of another leading generic pharmaceutical company, Accord Healthcare looks to continue to supply the generic medicine industry while mitigating the risks that come with acquisitions.
In an article dedicated to the generic medicines and the invaluable role they play, James Burt – Executive Vice-president of Accord Healthcare Europe and MENA – talks about how generics provide better value to taxpayers and better outcomes for the patients.
Accord Healthcare were honoured to be shortlisted in several categories at The Global Generics & Biosimilars Awards, taking place on Tuesday the 23rd of October.
Intas Pharmaceuticals completes deal to acquire Actavis UK & Ireland generics businesses.